Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
Caraway Therapeutics, Inc. logo — a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) |...

Caraway Therapeutics, Inc.

a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | Precision Medicines for CNS and Rare Diseases

Founded 2018 United States Cambridge, United States 4 employees Grant Total: $23.00M Biotechnology, Health Care +1

General Information

Company Name Caraway Therapeutics, Inc.
Founded Year 2018
Location United States Cambridge, United States +1
Founders / Decision Makers
Team member
Employees 4
Industries Biotechnology, Health Care, Health and Wellness
Funding Stage Grant
Social

Get notified when Caraway Therapeutics, Inc. moves

Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.

Free · no account needed

About Caraway Therapeutics, Inc.

Caraway Therapeutics, Inc. is a biotechnology startup founded in 2018, headquartered in the United States. The company's slogan, "Precision Medicines for CNS and Rare Diseases," reflects its focus on developing targeted therapies for neurodegenerative and rare diseases. Caraway's unique approach leverages genetic data to develop proprietary small molecules that activate cellular clearance and recycling processes, thereby accelerating the removal of toxic materials and defective cellular components. Their research focuses on the link between lysosomal function and pathologies in various organ systems, including the central nervous system, heart, kidney, and muscle. This makes the company a leader in developing potentially disease-modifying compounds for conditions such as Parkinson’s disease, Amyotrophic Lateral Sclerosis, and lysosomal storage diseases. Caraway's last investment, a grant from the Michael J. Fox Foundation in November 2020, highlights the recognition and support the company has received in its pursuit of innovative therapeutics.

Taxonomy: Precision Medicines, CNS Diseases, Rare Diseases, Cellular Clearance, Genetic Data, Lysosomal Function, Neurodegenerative Diseases, Parkinson's Disease, Amyotrophic Lateral Sclerosis, Lysosomal Storage Diseases, Therapeutic Approach, Biological Understanding, Disease-modifying Compounds, Toxic Materials Clearance, Proprietary Small Molecules

Funding Rounds & Investors (3)

View All
Funding Stage Amount Investors Lead Investors Date
Grant •••••• 1
Investor
18 Nov 2020
Venture Round •••••• 4
Investor Investor Investor Investor
01 Jan 2020
Series A •••••• 5
Investor Investor Investor Investor Investor
26 Nov 2018

Caraway Therapeutics, Inc. Alternatives & Competitors

Caraway Therapeutics, Inc. vs
Renatus
Renatus Korea South

Protect the world from cholesterol

1 employees
Pharmaceutical
Caraway Therapeutics, Inc. vs
Lysoway Therapeutics
Lysoway Therapeutics United States

Leading the way in lysosomal ion channel biology to address neurodegenerative diseases and metabolic...

Grant
7 employees
Biotechnology, Health and Wellness
Caraway Therapeutics, Inc. vs
Sharp Therapeutics
Sharp Therapeutics United States

Developing small molecule drugs for genetic diseases..

10 employees
Biopharma, Biotechnology

FAQ About Caraway Therapeutics, Inc.

a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | Precision Medicines for CNS and Rare Diseases
Caraway Therapeutics, Inc. was founded in 2018.
Caraway Therapeutics, Inc. is headquartered in Cambridge, United States.
Caraway Therapeutics, Inc. operates in the following industries: Biotechnology, Health Care, Health and Wellness.
Caraway Therapeutics, Inc. has approximately 4 employees.
Caraway Therapeutics, Inc. has completed 3 funding rounds, raising a total of $23.00M. The latest funding stage is Grant.
Top alternatives and competitors to Caraway Therapeutics, Inc. include Renatus, Lysoway Therapeutics, Sharp Therapeutics, Polaryx Therapeutics, Lime Therapeutics. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Caraway Therapeutics, Inc. and Renatus are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Don't just browse. Track.

Signal Tracker monitors Caraway Therapeutics, Inc. and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.

See how it works

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes